Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway

Krystal Biotech’s decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal Biotech’s KB707. The biotech said this has introduced “heightened uncertainty” regarding a potential accelerated pathway for the candidate.